Antiviral therapy for COVID-19 critical patients with respiratory distress syndrome
Deasy Wirasiti

RS Dustira
Faculty of Medicine, UNJANI

Abstract

Corona virus disease 2019 (COVID-19) is caused by the severe acute respiratory syndrome corona virus 2 (SARS-CoV-2), a newly emergent corona virus that was first recognized in Wuhan, Hubei province, China in Desember 2019. Severe acute respiratory syndrome corona virus 2 (SARS-CoV-2) is a positive-sense single stranded RNA virus that is contagious in humans, and also the successor to SARS-CoV-1, the strain that caused the 2002 until 2004 SARS outbreak.
Corona virus disease 2019 (COVID-19) can develop into critical disease with complications such as respiratory failure, an acute respiratory distress syndrome about 5% of all cases. Some antivirals currently used are oseltamivir, favipiravir, lopinavir/ritonavir and remdesivir. The guidelines from World Health of Organization (WHO) contains strong recommendation against the use of hydroxycholoroquine and lopinavir/ritonavir in patients with COVID-19, regardless of disease severity. A conditional recommendation against remdesivir in hospitalized patients with COVID-19. Both favipiravir and remdesivir can give better improvement to early COVID-19 patients.

Keywords: covid-19, antiviral, respiratory distress

Topic: Covid 19 in Emergency